Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study-Reference-Cited by-同舟云学术

Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study

Published:2022-09 Issue:9 Volume:33 Page:929-938
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Maio M.,Ascierto P.A.,Manzyuk L.,Motola-Kuba D.,Penel N.,Cassier P.A.,Bariani G.M.,De Jesus Acosta A.,Doi T.,Longo F.,Miller W.H.,Oh D.-Y.,Gottfried M.,Xu L.,Jin F.,Norwood K.,Marabelle A.

Funder

Sanofi

Chugai Pharmaceutical

AbbVie

Daiichi-Sankyo

Meso Scale Diagnostics

Boehringer Ingelheim

Novartis

Merck Sharp and Dohme

AstraZeneca

GlaxoSmithKline

Amgen

Bristol-Myers Squibb

Janssen Pharmaceuticals

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference26 articles.

1. Microsatellite instability as a biomarker for PD-1 blockade;Dudley;Clin Cancer Res,2016

2. DNA mismatch repair proteins: scientific update and practical guide;Bateman;J Clin Pathol,2021

3. PD-1 blockade in tumors with mismatch-repair deficiency;Le;N Engl J Med,2015

4. Association of programmed death ligand 1 expression with prognosis among patients with ten uncommon advanced cancers;Steiniche;Future Sci OA,2020

5. Landscape of microsatellite instability across 39 cancer types;Bonneville;JCO Precis Oncol,2017

Cited by 184 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunotherapeutic strategies in gastroesophageal tumors;Principles of Immunotherapy Breast and Gastrointestinal Cancers;2025

2. Small bowel cancers: A population-based analysis of epidemiology, treatment and outcomes in Ontario, Canada from 2005-2020;Surgical Oncology Insight;2024-12

3. Identifying and validating angiogenesis-related genes remodeling tumor microenvironment and suppressing immunotherapy response in gastric cancer;Gene;2024-11

4. Diffuse Gastric Cancer: A Comprehensive Review of Molecular Features and Emerging Therapeutics;Targeted Oncology;2024-09-13

5. The efficacy and safety of pembrolizumab and dostarlimab in advanced endometrial carcinoma: a systematic review;Discover Medicine;2024-09-10